Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: VIR

Vir Biotechnology, Inc.

Healthcare | Biotechnology

Market prices for VIR are shown to signed-in users (sign in). This public page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-1.86

Vir Biotechnology, Inc. (NASDAQ: VIR) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 09:47 UTC.

What Vir Biotechnology, Inc. does

Vir Biotechnology is a clinical-stage biopharmaceutical company developing medicines for serious infectious diseases and cancer by enhancing the immune system's ability to fight these threats. The company's clinical pipeline includes investigational therapies for hepatitis delta virus through its ECLIPSE program, which is evaluating a combination treatment in ongoing randomized controlled trials, and multiple Phase 1 oncology studies of dual-masked T-cell engagers targeting specific cancer types.

Summarized from Vir Biotechnology, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-1.86

Revenue, margins & earnings

FY2021 Revenue: $1.10B — margin split not shown (non-operating gains)$1.10BFY2021FY2022 Net income: $516MFY2022 Taxes & interest: $317MFY2022 Operating costs: $783M$1.62BFY2022FY2023: net loss $615M on revenue $86M$86MFY2023FY2024: net loss $522M on revenue $74M$74MFY2024FY2025: net loss $438M on revenue $69M$69MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-08-12
  • 2026-08-12DirectorOther8,000—
  • 2026-08-12DirectorOther-8,000—
  • 2026-06-10DirectorStock Option (Right to Buy)Award16,000—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Vir Biotechnology, Inc. do?

Vir Biotechnology is a clinical-stage biopharmaceutical company developing medicines for serious infectious diseases and cancer by enhancing the immune system's ability to fight these threats.

When did VIR last file with the SEC?

Vir Biotechnology, Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-24. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 09:47 UTC. This page is also available as JSON at /api/data?ticker=VIR and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for VIR and 5,000+ tickers.

Create a free account — keep VIR
For your agent
GET /api/data?ticker=VIR

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt